Browsing Tag
Ionis Pharmaceuticals
16 posts
Biogen stock (NASDAQ: BIIB) falls 8.2%: Can diranersen recover in Phase 3?
Biogen’s diranersen reduced tau and showed its strongest clinical result at the lowest dose, but the Phase 2 study missed its dose-response goal. With $BIIB down 8.2%, July 29 results and the Phase 3 design become the next tests.
Ionis Pharmaceuticals (IONS) drops 21% as Wainua Phase 3 ATTR-CM trial fails, Alnylam Amvuttra and BridgeBio Attruby emerge as clear beneficiaries
Ionis (IONS) drops 21% as Wainua Phase 3 ATTR-CM trial fails primary endpoint. Peak sales cut to $4B. Alnylam and BridgeBio benefit from the reset.
AstraZeneca (AZN) shares fall as Wainua Phase III trial miss dents ATTR-CM growth hopes
Read how AstraZeneca’s Wainua trial miss reshapes AZN stock sentiment, ATTR-CM competition and its 2030 growth story after July 9.
Could elsunersen become the asset that steadies Praxis Precision Medicines’ CNS pipeline?
Find out how Praxis’ FDA Breakthrough Therapy Designation for elsunersen could affect PRAX stock, rare epilepsy strategy and precision neuroscience today!
Kardigan’s IPO demand looks strong, but the real test for KARD arrives in 2027
Kardigan raises $400 million in an upsized Nasdaq IPO to fund three cardiovascular trials. Discover the catalysts, cash runway and risks for KARD investors.
GSK’s bepirovirsen wins FDA priority review as chronic hepatitis B strategy enters decisive phase
GSK has FDA momentum in hepatitis B. The harder question is whether bepirovirsen can turn functional cure into a real market shift.
Kardigan’s tonlamarsen data put acute severe hypertension into sharper commercial focus
Kardigan’s tonlamarsen Phase 2 data showed blood pressure promise despite mixed endpoints. Read what it means for acute severe hypertension next.
Can zilganersen become the first disease-modifying therapy for Alexander disease?
Ionis wins FDA breakthrough therapy status for zilganersen in Alexander disease. Find out what this means for rare neurology drug development.
Ionis and SOBI’s olezarsen cuts pancreatitis risk by 85% in sHTG phase 3 trials
Olezarsen showed 85% reduction in acute pancreatitis for severe hypertriglyceridemia. See what this means for Sobi, Ionis, and upcoming EMA and FDA filings.
Ionis Pharmaceuticals’ olezarsen reduces pancreatitis by 85% in late-stage sHTG trial
Ionis Pharmaceuticals reports 85% drop in pancreatitis with olezarsen in Phase 3 sHTG trial. Find out what the AHA late-breaker results could mean for FDA approval.